Halozyme Therapeutics HALO announced that it has entered into a definitive agreement with Antares Pharma ATRS to acquire the latter for approximately $960 million. The acquisition will add Antares’ ...
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Halozyme Therapeutics Inc is bolstering its drug delivery platform with a $960 million all-cash deal for specialty ...
EWING, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG ...
Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business ...
Pfizer has tapped Antares Pharma for the development of a self-administered combination drug-device rescue pen for an undisclosed medicine, shortly after investing $465 million in a new sterile ...
EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX: AIS - News) announced that the Company received a milestone payment from Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA - News) related to ...
Shares of Antares Pharma Inc. and Amag Pharmaceuticals soared in premarket trade Thursday, after Amag said the U.S. Food and Drug Administration has approved their Makena subcutaneous auto injector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results